Photo from outsourcing-pharma.com
Jun 18, 2023, 16:32
FDA approved our new bispecific antibody for treating people with relapsed or refractory Diffuse Large B-cell Lymphoma
In a post by on Linkedin, it says, “I’m excited to share that the FDA approved our new bispecific antibody for treating people with relapsed or refractory Diffuse Large B-cell Lymphoma(DLBCL). Despite the progress we’ve seen in treating DLBCL, additional treatment options are critical for those who relapse or are refractory to other treatments given the aggressive nature of this disease.
Today marks another great advancement for the blood cancer community and reinforces our steadfast commitment to those living with difficult-to-treat cancers.”
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 4, 2024, 18:01
Nov 4, 2024, 17:34
Nov 4, 2024, 17:17
Nov 4, 2024, 17:12
Nov 4, 2024, 16:51
Nov 4, 2024, 16:16